News

As part of the company governance changes, Cerba HealthCare announces that Philippe Buhl is leaving the company with effect from 1 February 2024.

He will no longer hold any corporate office within the Group, and in particular his position as Managing Director, which he has held since April 2023.

Philippe joined Cerba HealthCare in 2011.

MANAGEMENT TRANSITION AT CERBA HEALTHCARE

Lunar - Pricing Press Release

Cerba HealthCare provides update on recent trading

Lunar - Launch Press Release 18 Oct. 2021

Cerba HealthCare provides update on loan financing for acquisition of Lifebrain in Italy

Cerba HealthCare - Pricing Press Release

Cerba HealthCare - Launch Press Release

Cerba HealthCare, together with Partners Group and PSP Investments have entered into exclusive discussions with EQT to enable the Company to pursue its long-term innovation services strategy and enhance services for patients and the medical Community

Cerba HealthCare, a leading player in the field of clinical pathology in Europe, is establishing itself in Africa to develop Cerba Lancet Africa, a network of labs in partnership with Lancet Laboratories, South Africa’s leader in clinical pathology.

Acquisition of ACCOLAB

Cerba announced today that the acquisition of Bio IDF Santé ("BIO 7") has been completed

€60.0 million senior notes due 2025 pricing

Cerba HealthCare intends to offer €60.0 million in aggregate principal amount of its senior notes due 2025

Exclusive agreement signed

Cerba HealthCare announces the consolidation of its Italian business, Cerba HealthCare Italia, through the acquisition of Fleming Research — a firm with a network of diagnostic centres based in northern Italy (Lombardy and Piedmont).

Partners Group and PSP Investments have finalized the acquisition of Cerba HealthCare, a leading European operator of clinical pathology laboratories, from PAI Partners.

Notice of redemption

Paris, France, March 21, 2017. Cerba Healthcare S.A.S. and its affiliates (the “Cerba Group”) announced today that NewCo Sab MidCo S.A.S...

Conditional notice of redemption.

Cerba HealthCare - Launch Press Release

Cerba HealthCare S.A.S announces preliminary financial results for year end 2016 and expected redemption of existing notes.

Cerba HealthCare is announcing the acquisition of DELTAMEDICA, a medical group located in Northern Italy in the Milan region.

PAI Partners, a leading European private equity firm has entered exclusive negotiations with Partners Group, the global private markets investment manager, and the Public Sector Pensions Investment Board (“PSP Investments”), one of Canada’s largest pension investment managers, for the sale of Cerba HealthCare.

CERBA HEALTHCARE has announced the acquisition of ANTAGENE, a major player in veterinary genetics, consolidating its position in the veterinary diagnosis sector.

Cerba HealthCare S.A.S. (“Cerba” or the “Group”) today announces that it has successfully priced a private placement of €40 million aggregate principal amount of additional 7.00% Senior Secured Notes due 2020 directly with certain investors.

Bioponant, located in Brest and its region, joined the Cerba European Lab network this summer.

CERBA EUROPEAN LAB S.A.S. announces the closing of the NOVESCIA acquisition.

CERBA EUROPEAN LAB S.A.S. announces launch of offerings of €85 million in aggregate principal amount of 7.00% senior secured notes
and €145 million in aggregate principal amount of senior notes.

Clinical pathology group Cerba European Lab announces its takeover of JSBIO, a group of laboratories located in Bouches du Rhône, the Var, Vaucluse and Alpes Maritimes.

Cerba European Lab S.A.S. (the “Issuer”) today announced the commencement of a solicitation (the “Solicitation”) of consents...

CERBA EUROPEAN LAB S.A.S. announces launch of offering of €80 million in aggregate principal amount of 7.00% senior secured notes.

CERBA EUROPEAN LAB S.A.S. announces pricing of tap offering of senior secured notes.

CERBA EUROPEAN LAB S.A.S. announces receipt of requisite consents in connection with the consent solicitation relating to its 7.00% senior secured notes due 2020 and execution of the supplemental indenture.

Saint-Ouen-L’Aumône, France — Monday 14 January 2013. Cerba European Lab S.A.S. (“Cerba European Lab”) today announced that it has launched an offering of €355,000,000 aggregate principal amount of its senior secured notes due...